TAK-875
Sponsors
Takeda
Conditions
Cardiovascular DiseaseDiabetesDiabetes MellitusDiabetes Mellitus, Type 2Diabetic PatientsType 2 DiabetesType 2 Diabetes Mellitus
Phase 1
Phase 2
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
CompletedNCT01007097
Start: 2009-12-31End: 2010-09-30Updated: 2016-04-13
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
CompletedNCT01414920
Start: 2011-08-31End: 2012-08-31Updated: 2016-04-04
Phase 3
Long-term Study of TAK-875
CompletedNCT01433406
Start: 2011-10-31End: 2013-12-31Updated: 2014-01-27
Open-label Study of TAK-875
CompletedNCT01433419
Start: 2012-01-31End: 2012-12-31Updated: 2013-03-22
Double-blind Comparative Study of TAK-875
CompletedNCT01433393
End: 2012-09-30Updated: 2012-11-09
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
TerminatedNCT01481116
Start: 2012-01-31End: 2014-04-30Updated: 2016-06-01
Double Blind Comparative Study of TAK-875
CompletedNCT01585792
Start: 2012-05-31End: 2012-12-31Updated: 2013-04-16
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
TerminatedNCT01609582
Start: 2012-06-30End: 2014-05-31Updated: 2015-10-19
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
TerminatedNCT01647542
Start: 2012-10-31End: 2014-03-31Updated: 2015-11-11
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
TerminatedNCT01829464
Start: 2013-05-31End: 2014-03-31Updated: 2016-06-01
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
TerminatedNCT01829477
Start: 2013-04-30End: 2014-02-28Updated: 2016-06-01